Condensed Lactam Derivative for Neuropsychiatric Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications do not effectively target both serotonin 5-HT1A receptor agonism and 5-HT2A receptor antagonism simultaneously, which are crucial for treating neuropsychiatric diseases.
Innovation Solution
A novel compound with the specific structure, as defined by Formula (1), exhibiting antagonist activity for the 5-HT2A receptor and agonist activity for the 5-HT1A receptor, providing a therapeutic option for neuropsychiatric diseases by modulating these receptors effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate medications are used for 5-HT1A receptor agonism and 5-HT2A receptor antagonism, then each receptor can be targeted effectively, but the treatment requires multiple drugs and complex medication management
Solution Approach 1:
The patent combines the pharmacological activities of 5-HT1A receptor agonism and 5-HT2A receptor antagonism into a single compound structure (Formula 1), eliminating the need for separate medications and simplifying treatment regimens while maintaining effective targeting of both receptors
Solution Approach 2:
The compound of Formula 1 serves multiple functions simultaneously: it acts as both a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, making it a multi-functional medication that can treat various neuropsychiatric conditions with a single drug
2Reliability
If existing medications are used for neuropsychiatric diseases, then treatment is available, but metabolic stability is insufficient and persistence is short
Solution Approach 1:
The patent modifies molecular parameters of the compound structure (Formula 1) to optimize pharmacokinetic properties, resulting in improved metabolic stability and extended persistence in the human body compared to existing medications
3Adaptability or versatility
If non-selective serotonin receptor drugs are used, then broad receptor coverage is achieved, but selectivity and potency for specific receptors are reduced
Solution Approach 1:
The compound of Formula 1 exhibits local quality by demonstrating preferential binding and activity at specific receptors (5-HT1A and 5-HT2A) over other serotonin receptor subtypes, achieving both selectivity and broad coverage through its molecular structure
Data Source
AI summary
The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1):or a pharmaceutically acceptable salt thereof, as an active ingredient.